Neuvoir lands £99K Smart:Scotland grant for AI-driven NHS generics platform
What's the deal? Glasgow-based Neuvoir Pharmaceuticals has been awarded over £99,000 in Smart:Scotland funding from Scottish Enterprise to advance Pharmoris, its AI-enabled medicines intelligence platform. The grant will fund a nine-month feasibility study exploring how artificial intelligence can help the NHS identify, assess, and deploy high-value generic medicine opportunities more efficiently.
Pharmoris tackles a persistent problem in health systems: actionable medicines data, cost pressures, supply risks, and implementation decisions often sit across different teams and organisations, making opportunities hard to prioritise. The project will test whether AI-supported prioritisation models, regulatory workflow templates, and NHS deployment simulations can help close that gap.
Why now? Neuvoir was founded in Glasgow in 2025 and has been scaling quickly, having already received Innovate UK funding. The Smart:Scotland award builds on that momentum as the company positions itself at the intersection of medicines access, generics strategy, regulatory intelligence, and AI-enabled health-system infrastructure.
NHS cost pressures and supply-chain vulnerabilities have made generic medicines deployment an increasingly urgent priority across the UK.
What could go wrong? The project is explicitly a feasibility study — it aims to assess technical viability and commercial potential, not deliver a finished product. Whether Pharmoris can move from simulation to real-world NHS adoption remains an open question, particularly given the complexity of health-system procurement and governance.
Keeping clinical, regulatory, financial, and governance judgement within human teams — rather than automating it away — is a stated design goal, but striking that balance in practice will be a challenge.
The signal: Neuvoir's back-to-back public grants — first from Innovate UK, now from Scottish Enterprise — underscore a widening appetite among UK government funders for AI applied not to drug discovery but to the operational plumbing of medicines deployment and supply resilience. Still at early growth stage and founded only last year, the company's ability to stack non-dilutive funding suggests institutional confidence in the category, even if the commercial model remains unproven ahead of real NHS procurement conversations.
Read more: PharmaPress
